- New agreement with Lilly to license ATLX-1282, a first-in-class IND-ready programme for neurodegenerative conditions targeting a novel receptor and mechanism - Deal worth up to $415m including ...
U.K.-based biotech Alchemab on Tuesday announced a licensing agreement with Eli Lilly (NYSE:LLY) to jointly develop ATLX-1282, an early-stage therapeutic candidate targeting amyotrophic lateral ...
The MarketWatch News Department was not involved in the creation of this content. Agreement supports the research and development of up to five novel therapeutic antibodies identified through Alchemab ...
Alchemab Therapeutics Ltd. has entered into a licensing agreement with Eli Lilly and Co. for ATLX-1282, Alchemab’s first-in-class IND-ready program targeting a novel receptor and mechanism for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback